As a pioneering CDMO to the psychedelic sector, Psygen is committed to leading and empowering the industry by creating a robust supply chain solution – now and in the future.
The Psychedelics Industry Needs a Dedicated Manufacturer
Psygen’s 17,000 sq. ft. state-of-the art, GMP-compliant facility will enable large-scale synthesis of psychedelic compounds in a production area of 6,000 sq. ft.
Psygen has received a Health Canada dealer’s license which allows the manufacture, sale, import, export, and analysis of LSD, 2C-B, DMT, MDMA, psilocybin, and mescaline.
Contract Development & Manufacturing
Psygen’s team provides over 50 years of combined expertise synthesizing psychedelics and will actively support your projects throughout development and commercialization processes.
Psygen will supply the industry with safe and reliable GMP synthetic psychedelics to enable clinicians and researchers to deliver safe treatments while achieving optimal treatment outcomes.
Our focus on synthetic compounds, Psygen is able to produce quality-consistent products on a large scale, allowing us to meet increasing demand while reducing the cost of production and indirectly protecting culturally sensitive plant populations. Psygen’s API catalogue includes psychedelics for which no natural sources exist, such as LSD, 2C-B, and MDMA.
Connecting the industry
Psygen aims to contribute to the growth of the global psychedelics research ecosystem.
Psygen will create trusting relationships shaped by ingenuity and generosity – and our belief in the value of creating positive, genuine connections.
Global access to pharmaceutical grade psychedelics is limited. Psygen works for the benefit and advancement of the psychedelic industry to expand and serve new markets.